INSTI Accessory Mutations:			None			
IN Other Mutations:			S17N • R20K • L28I • S39C • T1			
	Integ	rase Strand	Transfer Ini	nibitors		
bictegravir (BIC)			Potential Low-Level Resistance			
cabotegravir (CAB)			Low-Level Resistance			
dolutegravir (DTG)			Potential Low-Level Resistance			
elvitegravir (EVG)			High-Level Resistance			
raltegravir (RAL)			High-Level Resistance			
IN commen	ts					
Major						
• N155	H is a comm	non nonpoly	morphic INS	T1-resistano	e mutations.	
<ul> <li>This</li> </ul>	virus is pred	licted to have	e low-level re	educed suso	eptibility to <b>C</b>	
Mutation s	coring: IN					
Drug resista	nce mutatio	n scores of IN	ISTI:	Download CSV -		
Rule	BIC ÷	CAB ≑	DTG ÷	EVG ‡	RAL ÷	
N155H	10	25	10	60	60	

Drug resistance interpretation: IN

INSTI Major Mutations:

T124A • T125A • V201I • I208L It has been reported in a high proportion of persons developing VF and HIVDR while receiving RAL, EVG, DTG, and CAB. Alone, it reduces RAL and EVG susceptibility about 10 and 30-fold, respectively. It has minimal effect on susceptibility to DTG, BIC, and CAB. CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated. HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)